Focus on strategies that treat patients before they go on opioids, says a medical doctor and medtech innovator speaking in an upcoming MD&M West 2019 panel discussion.
Israel-based Itamar Medical plans to use the net proceeds to accelerate its revenue growth through direct expansion of its sales and marketing initiatives.
FDA cannot accept new 2019 user fees during the government shutdown, which means the agency cannot accept new medical product applications.
The acquisition comes hot on the heels of Boston Scientific making a significant acquisition into the mitral valve space.
The Irvine, CA-based company is slated to pay out $180 million to Boston Scientific in a move that would end both firms’ outstanding TAVR lawsuits and injunctions.
Abbott says its Amplatzer Piccolo Occluder is the first device approved for use in the tiniest babies (weighing as little as two pounds) to treat patent ductus arteriosus, a common congenital defect.
FDA has granted AWAK Technologies a breakthrough device designation for a wearable and ultra-portable peritoneal dialysis device.
The MD&M West Conference Feb. 5-7 in Anaheim, CA will feature a curated roster of speakers with deeply-technical expertise in everything from new technology and next-generation design, to product development, new materials, product testing, and quality.
Key changes include sections guiding education and marketing programs, communication on safe and effective use of medtech, and on providing technical support. The update also expands provisions on support for third-party educational and other conferences.
Each year the J.P. Morgan Healthcare Conference serves as the start of medtech’s season. Now that it has ended, here are 7 key things we learned about companies presenting during the event.
The San Clemente, CA-based firm is developing several glaucoma treatment products as it transitions into a hybrid surgical, pharmaceutical, and medical device company.
The San Diego-based company presented at the 37th annual J.P. Morgan Healthcare Conference and said its revenue increased by 43% in 2018 despite mounting competition from rivals.
Google’s former life sciences division said it would use the proceeds from the $1 billion investment round to help with its collaborations and potential acquisitions.